Download PDF
CC BY 4.0 · TH Open 2022; 06(03): e154-e155
DOI: 10.1055/s-0042-1749092
T&H Images

Emicizumab-induced photosensitivity

Pedro Asensi Cantó 
1   Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital La Fe, Valencia, Spain
,
Mercedes Rodríguez Serna
2   Servicio de Dermatología, Hospital La Fe, Valencia, Spain.
,
Pilar Lloret Madrid
1   Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital La Fe, Valencia, Spain
,
Jürgen Solís Ruiz
1   Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital La Fe, Valencia, Spain
,
Ana Rosa Cid Haro
1   Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital La Fe, Valencia, Spain
,
Santiago Bonanad Boix
1   Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital La Fe, Valencia, Spain
,
Saturnino Haya Guaita 
1   Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital La Fe, Valencia, Spain
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression. To the best of our knowledge, this side effect had not been communicated until present.

Keywords

hemophilia therapy - hemostasis - hemophilia A/B


Publication History

Received: 03 December 2021

Accepted: 11 April 2022

Article published online:
21 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany